TY - JOUR
T1 - A multicentre validation study of the diagnostic value of plasma neurofilament light
AU - Ashton, Nicholas J
AU - Janelidze, Shorena
AU - Al Khleifat, Ahmad
AU - Leuzy, Antoine
AU - van der Ende, Emma L
AU - Karikari, Thomas K
AU - Benedet, Andrea L
AU - Pascoal, Tharick A
AU - Lleó, Alberto
AU - Parnetti, Lucilla
AU - Galimberti, Daniela
AU - Bonanni, Laura
AU - Pilotto, Andrea
AU - Padovani, Alessandro
AU - Lycke, Jan
AU - Novakova, Lenka
AU - Axelsson, Markus
AU - Velayudhan, Latha
AU - Rabinovici, Gil D
AU - Miller, Bruce
AU - Pariante, Carmine
AU - Nikkheslat, Naghmeh
AU - Resnick, Susan M
AU - Thambisetty, Madhav
AU - Schöll, Michael
AU - Fernández-Eulate, Gorka
AU - Gil-Bea, Francisco J
AU - López de Munain, Adolfo
AU - Al-Chalabi, Ammar
AU - Rosa-Neto, Pedro
AU - Strydom, Andre
AU - Svenningsson, Per
AU - Stomrud, Erik
AU - Santillo, Alexander
AU - Aarsland, Dag
AU - van Swieten, John C
AU - Palmqvist, Sebastian
AU - Zetterberg, Henrik
AU - Blennow, Kaj
AU - Hye, Abdul
AU - Hansson, Oskar
N1 - Funding Information:
This study is independent research partly funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. This project was partly funded by the MND Association and the Wellcome Trust. This is an EU Joint Programme-Neurodegenerative Disease Research (JPND) project. The project is supported through the following funding organizations under the aegis of JPND—www.jpnd.eu (United Kingdom, Medical Research Council MR/L501529/1, MR/ R024804/1) and Economic and Social Research Council (ES/L008238/1)). A.A.C. is an NIHR Senior Investigator and receives salary support from the National Institute for Health Research (NIHR) Dementia Biomedical Research Unit at South London and Maudsley NHS Foundation Trust and King’s College London. The work leading up to this publication was funded by the European Community’s Health Seventh Framework Program (FP7/2007–2013; grant agreement number 259867) and Horizon 2020 Program (H2020-PHC-2014-two-stage; grant agreement number 633413). This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement 772376 - EScORIAL. Work at Lund University was supported by the European Research Council, the Swedish Research Council, the Knut and Alice Wallenberg Foundation, the Marianne and Marcus Wallenberg Foundation, the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s disease) at Lund University, the Swedish Alzheimer Foundation, the Swedish Brain Foundation, The Parkinson Foundation of Sweden, The Parkinson Research Foundation, the Skåne University Hospital Foundation, and the Swedish federal government under the ALF agreement. Doses of 18F-flutemetamol injection were sponsored by GE Healthcare. We are grateful to participants in the BLSA for their invaluable contribution. This study was supported in part by the intramural research program of the National Institute on Aging (NIA), National Institutes of Health (NIH). N.J.A. is funded by the Wallenburg Centre for Molecular and Translational, Swedish Alzheimer Foundation (Alzheimerfonden), the Swedish Dementia Foundation (Demensfonden), Hjärnfonden (#FO2020-0241) and Gamla Tjänarinnor. A.A.K is funded by The Motor Neurone Disease Association (MNDA) and NIHR Maudsley Biomedical Research Centre. G.F.-E. was supported by the neuromuscular diseases (GEEN) of the Spanish Society of Neurology (SEN) and the SEN itself. A.S. has received grants from a Wellcome Trust Strategic Award (grant number 098330/Z/12/Z conferred upon The London Down Syndrome (LonDownS) Consortium), and the UK Medical Research Council (Medical Research Council grants MRC S011277/1, MR/S005145/1 via Centres of Excellence in Neurodegeneration research, and MR/R024901/1 via JPND) and the work was further supported by the National Institute for Health Research networks (mental health, dementias, and neurology) and participating NHS trusts. P.S. is a Wal-lenberg Clinical Scholar and also funded by CBD solutions, Stockholm City Council, Swedish Foundation for Strategic Research and Van Geest Foundation. H.Z. is a Wal-lenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931) and the UK Dementia Research Institute at UCL. K.B. is supported by the Torsten Söderberg Foundation, Stockholm, Sweden. We would also like to acknowledge Lieke H Meeter in contributing to the collection of the samples.
Publisher Copyright:
© 2021, The Author(s).
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/6/7
Y1 - 2021/6/7
N2 - Increased cerebrospinal fluid neurofilament light (NfL) is a recognized biomarker for neurodegeneration that can also be assessed in blood. Here, we investigate plasma NfL as a marker of neurodegeneration in 13 neurodegenerative disorders, Down syndrome, depression and cognitively unimpaired controls from two multicenter cohorts: King's College London (n = 805) and the Swedish BioFINDER study (n = 1,464). Plasma NfL was significantly increased in all cortical neurodegenerative disorders, amyotrophic lateral sclerosis and atypical parkinsonian disorders. We demonstrate that plasma NfL is clinically useful in identifying atypical parkinsonian disorders in patients with parkinsonism, dementia in individuals with Down syndrome, dementia among psychiatric disorders, and frontotemporal dementia in patients with cognitive impairment. Data-driven cut-offs highlighted the fundamental importance of age-related clinical cut-offs for disorders with a younger age of onset. Finally, plasma NfL performs best when applied to indicate no underlying neurodegeneration, with low false positives, in all age-related cut-offs.
AB - Increased cerebrospinal fluid neurofilament light (NfL) is a recognized biomarker for neurodegeneration that can also be assessed in blood. Here, we investigate plasma NfL as a marker of neurodegeneration in 13 neurodegenerative disorders, Down syndrome, depression and cognitively unimpaired controls from two multicenter cohorts: King's College London (n = 805) and the Swedish BioFINDER study (n = 1,464). Plasma NfL was significantly increased in all cortical neurodegenerative disorders, amyotrophic lateral sclerosis and atypical parkinsonian disorders. We demonstrate that plasma NfL is clinically useful in identifying atypical parkinsonian disorders in patients with parkinsonism, dementia in individuals with Down syndrome, dementia among psychiatric disorders, and frontotemporal dementia in patients with cognitive impairment. Data-driven cut-offs highlighted the fundamental importance of age-related clinical cut-offs for disorders with a younger age of onset. Finally, plasma NfL performs best when applied to indicate no underlying neurodegeneration, with low false positives, in all age-related cut-offs.
UR - http://www.scopus.com/inward/record.url?scp=85107306441&partnerID=8YFLogxK
U2 - 10.1038/s41467-021-23620-z
DO - 10.1038/s41467-021-23620-z
M3 - Article
C2 - 34099648
SN - 2041-1723
VL - 12
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 3400
ER -